Daiichi Sankyo’s COVID-19 vaccine selected by Japanese drug discovery body

TOKYO – Daiichi Sankyo Co <4568.T> said on Monday that its mRNA-based COVID-19 vaccine candidate was selected for inclusion in a drug discovery program by the Japan Agency for Medical Research and Development.
The vaccine, known as DS-5670, was picked for the second round of AMED’s program dedicated to COVID-19 research. Daiichi Sankyo is aiming to begin clinical studies of the vaccine around March 2021 in collaboration with the University of Tokyo. REUTERS

Lohit Soundarajan

Founder , Editor Tech Guy #Voxguy

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button